Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration) 

 
Ticiana Leal, Yating Wang, Afshin Dowlati, et al.
 
The abstract concludes: 
The addition of nivolumab to CE as 1L treatment for ES-SCLC significantly improved PFS and OS. No new safety signals were observed. Clinical trial information: NCT03382561
————————————————————————————————————————————————————————
 
 
Charles M. Rudin, Mark M. Awad, Alejandro Navarro, et al.
 
The abstract concludes: 
Pembro + EP significantly improved PFS and prolonged OS compared with placebo + EP as first-line therapy for pts with ES-SCLC. No unexpected toxicities were seen with pembro + EP. These data support the benefit of pembro-containing regimens for ES-SCLC. Clinical trial information: NCT03066778
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————
 
 
Luis G. Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.
 
The abstract concludes: 
The addition of durvalumab to EP continued to demonstrate improvement in OS compared with a robust control arm, further supporting this regimen as a new standard of care for 1L ES-SCLC offering the flexibility of platinum choice. No additional benefit was observed when T was combined with D + EP in this pt population. Safety findings in all arms remained consistent with the known safety profiles of all agents. Clinical trial information: NCT03043872
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————
 
 
Patrick M. Forde, Zhuoxin Sun, Valsamo Anagnostou, et al.
 
The abstract concludes: 
The combination of chemotherapy with durvalumab delivered a promising median OS for previously untreated pts with unresectable MPM. Full results from the study along with the extensive correlative analyses performed will be reported. The phase 3 PrE0506/DREAM3R trial evaluating CP-durvalumab versus CP alone will commence enrollment in the United States and Australia in 2020. Clinical trial information: NCT02899195
————————————————————————————————————————————————————————
 
 
Maria Pagano, Giovanni Luca Ceresoli, Paolo Andrea Zucali, et al.
 
The abstract concludes: 
In the RAMES Study the addition of Ramucirumab to Gemcitabine significantly improved OS regardless of age of pts, tumor histotype and TTP at the first-line treatment. Gemcitabine plus Ramucirumab can be considered a manageable regimen in second-line treatment of advanced MPM pts.Clinical trial information: NTC03560973.
————————————————————————————————————————————————————————
 
The abstract concludes: 
In the RAMES Study the addition of Ramucirumab to Gemcitabine significantly improved OS regardless of age of pts, tumor histotype and TTP at the first-line treatment. Gemcitabine plus Ramucirumab can be considered a manageable regimen in second-line treatment of advanced MPM pts.Clinical trial information: NTC03560973.
 
Read the comment in the ASCO DAILY NEWS:
—————————————————————————————————————————————————————————————————————————————
 
 
Hirotsugu Kenmotsu, Seiji Niho, Masahiro Tsuboi, et al.
 
The abstract concludes: 
This study failed to show the superiority of IP to EP in RFS for pts with completely resected HGNEC. EP is still a standard treatment for this population. Clinical trial information: UMIN000010298.
————————————————————————————————————————————————————————
 
 
Bjorn Henning Gronberg, Kristin Toftaker Killingberg, Øystein Fløtten, et al.
 
The abstract concludes: 
LD SCLC patients who received BID TRT of 60 Gy had a statistically significant and numerically substantial benefit in terms of 2-year survival (primary endpoint) and median overall survival compared with those who received BID TRT of 45 Gy. The higher TRT dose did not cause more toxicity than the standard dose. Clinical trial information: NCT02041845
————————————————————————————————————————————————————————
 
 
DISCUSSANT
Percy Lee, MD | University of Texas MD Anderson Cancer Center
————————————————————————————————————————————————————————
 
Poster Abstract

9036 Efficacy of DNA versus RNA NGS-based Methods in MET Exon 14 skipping mutation detection.

Magdalena Jurkiewicz, Anjali Saqi, Mahesh M Mansukhani, et al.

The abstract concludes: 
DNA based NGS-panels can potentially miss MET-ex14 skipping events in lung carcinomas, when the primers do not target both 3′ splice site of intron 13, and the 5′ splice site of intron 14. A reflex work flow interrogating RNA fusions can potentially capture such events. The clinical and molecular characterization of the variants detected only by RNA NGS assays warrants further exploration.
 
Simultaneously published on NEJM:

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

P.K. Paik and Others

————————————————————————————————————————————————————————

9069 RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.

David R. Spigel, Luis G. Paz-Ares, Yuanbin Chen, et al.

The abstract concludes:

ORR and DCR12wks were numerically higher in platinum-sensitive than in platinum-resistant patients with SCLC who had progressed with platinum-based 1L therapy before receiving 2L liposomal irinotecan 70 mg/m2 in this phase 2 study. RESILIENT part 2, an ongoing, phase 3, randomized controlled trial vs topotecan, will provide further data. Clinical trial information: NCT03088813

CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
view slide set
————————————————————————————————————————————————————————

TPS9081 RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.

Luis G. Paz-Ares, David R. Spigel, Yuanbin Chen, et al.

  • The primary endpoint is overall survival (OS) and secondary endpoints are progression-free survival (PFS), objective response rate, and proportion of patients reporting symptom improvement.

Clinical trial information: NCT03088813

————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Clinical Science Symposium
 
Poster Discussion Session
 
Poster Session
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Lung (Abstracts #LBA5, 9000, 9001)
Access Content Now